Informativo

• Dual antiplatelet therapy (DAPT) with ticagrelor (e.g., Brilinta) outperforms aspirin alone at maintaining saphenous vein patency after coronary artery bypass grafting (CABG).
• Editorial notes relationship between vein patency and clinical outcomes is not straightforward, adding, “it is premature to endorse the routine addition of ticagrelor to aspirin after CABG surgery.”

Why this matters

• Early saphenous graft failure rates can reach 20%.
• Role of DAPT after CABG is unclear.